269 related articles for article (PubMed ID: 23067527)
1. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker.
Ozcan Kara P; Kara T; Kaya B; Kara Gedik G; Sari O
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):257-60. PubMed ID: 23067527
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence.
Sharma P; Kumar R; Singh H; Jeph S; Sharma DN; Bal C; Malhotra A
Clin Nucl Med; 2012 Jul; 37(7):649-55. PubMed ID: 22691505
[TBL] [Abstract][Full Text] [Related]
3. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
4. Splenic and multiple abdominal metastases of endometrial carcinoma detected with FDG-PET/CT.
Kara T; Kara PO; Gedik GK; Sari O
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):31-3. PubMed ID: 21737185
[TBL] [Abstract][Full Text] [Related]
5. [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Wang Q; Hong L; Wang JL; Yue MG; Li HB; Li Y
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):300-3. PubMed ID: 20510085
[TBL] [Abstract][Full Text] [Related]
6. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
[TBL] [Abstract][Full Text] [Related]
7. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
8. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
9. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT.
Crivellaro C; Signorelli M; Guerra L; De Ponti E; Pirovano C; Fruscio R; Elisei F; Montanelli L; Buda A; Messa C
Gynecol Oncol; 2013 Aug; 130(2):306-11. PubMed ID: 23707673
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of efficacy and clinical impact of FDG-PET in patients with suspicion of recurrent colorectal cancer].
Borrego Dorado I; Gómez Camarero P; Ruiz Franco-Baux J; Vázquez Albertino R
Rev Esp Med Nucl; 2004; 23(5):313-23. PubMed ID: 15450136
[TBL] [Abstract][Full Text] [Related]
11. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
13. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.
Belhocine T; De Barsy C; Hustinx R; Willems-Foidart J
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1132-9. PubMed ID: 12192557
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
16. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
17. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
18. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
[TBL] [Abstract][Full Text] [Related]
19. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
